Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS...
10 April 2023
In The Lancet HIV, CAPRISA’s Dr Sharana Mahomed and colleagues report results of a phase 1 safety and pharmacokinetics study of a combination of two long-acting anti-HIV broadly neutralising monoclonal antibodies (bNAbs), CAP256V2LS and VRC07l523LS, in women in South Africa.
For further reading see: Mahomed S, et al.Lancet HIV.2023.doi:10.1016/S2352-3018(23)00003-6
